INIA Biosciences

What INIA Biosciences does

INIA Biosciences is a private, pre-commercial medical device company founded in 2020–2021 and headquartered in Boston, with a parallel co-founder presence in Oxford, United Kingdom. The company is developing a non-invasive, home-administered, closed-loop bioelectronic platform that uses ultrasound (sound waves) to modulate the immune system for the management of chronic inflammatory diseases. Its single product line combines therapeutic ultrasound with proprietary diagnostic sensing in a closed-loop architecture, enabling at-home patient use and continuous treatment adjustment. The technology is described as bio-sonar inspired (the company name references the river dolphin Inia geoffrensis) and is positioned as a platform potentially applicable across multiple chronic inflammatory indications.

The company has no commercial revenue and no disclosed pricing; its forward business model anticipates hardware sales of proprietary bioelectronic medical devices to healthcare systems and/or direct-to-patient home-use distribution, with potential additional revenue from partnerships, licensing deals, or co-development arrangements with pharmaceutical or medical device companies. Go-to-market signals point toward an enterprise medtech motion — clinical validation, physician adoption, and healthcare-system procurement — supplemented by a heavy event-driven presence at industry conferences (AdvaMed MedTech Conference, Wilson Sonsini Medical Device Digital Health Conference, MassMEDIC BioMEDevice) and accelerators (MedTech Innovator 2024 cohort, Creative Destruction Lab Oxford, MIT IDEA^2, MassChallenge 2021, UMass M2D2 IMPACT).

INIA is led by co-founders CEO Dragana Savic (former Oxford academic, McKinsey Achievement Award winner) and CSO Shen Ning, supported by three named advisors — former Cala Health CEO Renee Ryan, former GE Healthcare COO Brian Wagner, and ANKH Impact Ventures founder Pierre Rolin — and operates with a small core team plus periodic intern cohorts. Funding to date is non-dilutive: an NSF STTR Phase I grant awarded in April 2024, supplemented by accelerator participation and grant support from MIT Sandbox, MIT 100K, ASU Innovation Open grand prize, and similar programs. The company is currently soliciting partnerships and investors for an upcoming raise, and has not yet filed patents publicly nor announced FDA submissions.

Name

INIA Biosciences

Legal name

INIA Biosciences Inc.

Website

https://iniabiosciences.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Short description

INIA Biosciences is a private Boston-based medical device company developing non-invasive, home-administered, closed-loop bioelectronic devices that use ultrasound to modulate the immune system and manage chronic inflammatory diseases.

Ownership category

akta.pro rank

Product category

Bioelectronic Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510), Surgical and Medical Instrument Manufacturing (339112), Medical Equipment and Supplies Manufacturing (3391)

SIC

Electromedical & Electrotherapeutic Apparatus (3845), Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Ultrasound & Echography Systems (HLAHABAD)

akta.pro secondary industry

Autoimmune & Allergy Diagnostics (HLAAALAK)

Keywords

• Bioelectronic medicine
• Ultrasound medical devices
• Chronic inflammatory treatment
• Non-invasive therapeutics
• Closed-loop medical devices

Headquarters

HQ city

Boston

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel

Revenue model

1. Medical Device Sales: Revenue from sale of proprietary bioelectronic medical devices for chronic inflammatory disease treatment. As a medical device company, likely to involve device sales to healthcare systems, hospitals, and potentially direct-to-patient home-use devices.
2. Partnership and Investment Revenue: The company is currently evaluating partnerships and raising capital. Future revenue may include strategic partnerships, licensing deals, or co-development arrangements with pharmaceutical or medical device companies.

Go-to-market motion2 records

Marketing channels6 records

Core offering

INIA Biosciences develops non-invasive, home-administered, closed-loop medical devices that use ultrasound (sound waves) to modulate the immune system for the management of chronic inflammatory diseases. The flagship product line integrates therapeutic ultrasound with proprietary diagnostic sensing in a closed-loop system, enabling patients to receive treatment at home without surgery, implants, or clinic visits. The company is pre-commercial and is currently building toward regulatory pathways and commercialization.

Product overview

INIA Biosciences is developing a single product line of bioelectronic treatment devices using non-invasive ultrasound technology to manage chronic inflammatory diseases. The company's flagship offering combines therapeutic ultrasound with novel diagnostic sensing in a closed-loop system, enabling home-administered treatment. The device leverages bioelectronic medicine principles to modulate the immune system through sound waves, representing a next-generation approach to bioelectronic medicine.

Differentiator

Problem solved

Functional benefit

Products and services

• Bioelectronic Treatment Device Non-invasive ultrasound-based medical device that uses sound waves to modulate the immune system and manage chronic inflammatory diseases, featuring home-monitoring and closed-loop therapeutic capabilities for patients with chronic inflammatory conditions.

Quantifiable outcome

• Non-invasive immune modulation without surgery or implants

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• MedTech InnovatorcoreGTM or Marketing PartnerINIA Biosciences was selected as one of 65 startups from approximately 1,300 applicants for MedTech Innovator's 2024 cohort. The company participates in a four-month accelerator program with mentorship, industry events, and funding competition opportunities. Cohort companies have raised over $2B combined.
• Cala Health (Advisor: Renee Ryan)minorOthersRenee Ryan, former CEO of Cala Health, serves as an advisor to INIA Biosciences, bringing over 25 years of healthcare investment and leadership experience.
• GE Healthcare (Advisor: Brian Wagner)minorOthersBrian Wagner, former COO of GE Healthcare, serves as an advisor to INIA Biosciences, contributing over 20 years of global operating and consulting experience in early-stage and Fortune 500 companies.
• ANKH Impact Ventures (Advisor: Pierre Rolin)minorOthersPierre Rolin, Founder and CEO of ANKH Impact Ventures, serves as an advisor to INIA Biosciences, bringing over 37 years of venture capital and real estate investment advisory experience.
• MIT Koch Institute for Integrative Cancer ResearchminorStrategic or Co-development PartnerINIA Biosciences CTO Shen Ning showcased the science behind INIA at the Koch Institute for Integrative Cancer Research at MIT, indicating potential research collaboration.
• University of OxfordminorStrategic or Co-development PartnerINIA co-founders originated from University of Oxford; the company maintains connections through internship programs with Oxford University students and Creative Destruction Lab Oxford Programme participation.
• Boston UniversityminorStrategic or Co-development PartnerINIA Biosciences participated in Boston University's New Venture Competition and M2D2 programs, with team members from BU including intern Briana Le.
• Creative Destruction Lab (Oxford Programme)coreGTM or Marketing PartnerINIA was accepted to and completed the Creative Destruction Lab Oxford Programme 2022/2023, receiving mentorship and support from the accelerator.

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Emerging players

• Soterix Medical: Soterix Medical develops non-invasive brain stimulation and neuromodulation technologies (tDCS, tACS, tTIS) for research and clinical applications. Emerging peer: both develop non-invasive, device-based neuromodulation platforms; Soterix focuses more on CNS research markets while INIA targets chronic inflammatory diseases.
• Spark Biomedical: Spark Biomedical develops neurostimulation devices, including subcutaneous auricular nerve stimulation for opioid withdrawal and post-partum depression. Emerging peer: comparable development-stage company using electrical neurostimulation for chronic conditions; complementary technology approach to INIA's ultrasound-based approach.

Broad incumbents

• Inspire Medical Systems: Inspire Medical Systems developed and commercializes an FDA-approved implantable neurostimulation device for obstructive sleep apnea. Broad incumbent: relevant comparator for understanding the clinical-trial-to-commercialization journey for implanted neurostimulation devices; Inspire is publicly traded and provides valuation benchmarks.
• NeuroPace: NeuroPace developed the RNS System, a closed-loop responsive neurostimulation device for epilepsy. Broad incumbent: both develop closed-loop implantable neurostimulation devices; NeuroPace is commercially launched (FDA-approved) and provides a benchmark for INIA's closed-loop ambulatory neurostimulation vision.
• Medtronic (Neuromodulation): Medtronic is a global medical device leader with a large Neuromodulation business (spinal cord, deep brain, sacral nerve stimulation). Broad incumbent: most relevant large strategic competitor/acquirer for bioelectronic medicine IP; represents both a risk (IP overlap) and opportunity (exit/strategic partnership).
• CVRx: CVRx developed Barostim, an FDA-approved neuromodulation device for heart failure and resistant hypertension. Broad incumbent: represents a successful path from R&D through FDA approval to commercialization for a bioelectronic medicine company; serves as a benchmark for INIA's commercialization pathway.
• Abbott (Neuromodulation): Abbott operates a major Neuromodulation franchise including Proclaim XR (DRG stimulation) and Prodigy (spinal cord stimulation). Broad incumbent: representative of large strategic players in adjacent neuromodulation; Abbott also has a partnership with Cala Health, illustrating the strategic interest from large medtech in bioelectronic medicine.

Direct peers

• electroCore: electroCore manufactures gammaCore, a non-invasive vagus nerve stimulation (nVNS) device for migraine and cluster headache. Direct peer: both develop non-invasive, home-administered bioelectronic devices for chronic conditions; gammaCore is the closest commercial analog to INIA's go-to-market positioning.
• Setpoint Medical: Setpoint Medical is developing bioelectronic medicine for chronic inflammatory diseases using vagus nerve stimulation (an implanted device). Direct peer: both target chronic inflammatory diseases via bioelectronic mechanisms; Setpoint is the most direct competitor in INIA's lead therapeutic area.
• Cala Health: Cala Health is the leading non-invasive bioelectronic medicine company, commercializing TAPS (Transcutaneous Afferent Patterned Stimulation) therapy for essential tremor. Direct peer: both target chronic conditions with non-invasive, wearable, closed-loop bioelectronic devices; INIA's CEO advisor (Renee Ryan) is the former CEO of Cala.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/inia-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles9 records

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about INIA Biosciences